All News
Filter News
Found 2,730 articles
-
ArsenalBio will focus on integrating various technologies, including CRISPR, synthetic biology, and machine learning to discover and develop immunotherapies, initially for oncology.
-
Jennifer Doudna, Ph.D., to be Named Recipient of CLSA’s Life Sciences Leadership Award at 2019 Pantheon DiNA™ Awards
10/17/2019
Visionary Leader in CRISPR Gene Editing Technology and Nominee for Nobel Prize in Chemistry to be Honored for Contributions to California’s Life Sciences Sector on Nov. 15
-
IDT Launches Custom Enrichment Panels for Faster, Lower Cost NGS at ASHG 2019
10/17/2019
NGS Discovery Pools enable larger custom panels and low sample numbers to speed up discovery
-
Intellia Therapeutics Announces Presentations at the 2019 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT)
10/16/2019
Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced one oral presentation and four poster presentations were accepted for the 27th Annual Congress of the European Society of Gene and Cell Therapy (ESGCT) taking place October 22-25, 2019, in Barcelona, Spain.
-
The research was published in the journal Nature Immunology.
-
Editas Medicine and AskBio Enter Strategic Research Collaboration to Explore In Vivo Delivery of Genome Editing Medicines to Treat Neurological Diseases
10/15/2019
This collaboration brings together AskBio’s leading capsid development, clinical stage AAV vector delivery system, and manufacturing expertise with Editas Medicine’s leading genome editing technologies to potentially develop novel medicines for patients with high unmet need.
-
CRISPR Therapeutics and KSQ Therapeutics Announce License Agreement to Advance Companies’ Respective Cell Therapy Programs in Oncology
10/15/2019
KSQ Therapeutics to receive non-exclusive access to certain CRISPR IP for its autologous cell therapies, including its existing eTIL™ cell franchise
-
Avellino Labs Receives CLIA Certification for Its AvaGen Genetic Diagnostic Test for Keratoconus and Corneal Dystrophies
10/14/2019
Genetic Diagnostic and Therapeutic Technology Company Initiates a Controlled Market Introduction of AvaGen in the U.S. with Nationwide Roll-out Expected in 2020
-
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
Beam Therapeutics Appoints Graham Cooper to Board of Directors
10/10/2019
Mr. Cooper was previously the chief financial officer and chief operating officer of Assembly Biosciences, a biotechnology company developing innovative therapeutics targeting hepatitis B virus.
-
Mustang Bio Announces City of Hope Receives $4.1 Million in Grant Awards for Recently Opened First-of-Its-Kind Clinical Trial for Patients with Recurrent Malignant Glioma
10/10/2019
Mustang Bio, Inc. congratulated City of Hope, a world-renowned independent cancer research and treatment center, on its receipt of $4.1 million in grant awards for a clinical trial of MB-101 in combination with nivolumab and ipilimumab in patients with recurrent malignant glioma.
-
During his 14-year tenure as head of BIO, Greenwood oversaw a significant growth at the organization, more than tripling its size to 176 employees with an 85 million operating budget.
-
Acorda Therapeutics’ attempt to preserve its patent protection for multiple sclerosis drug Ampyra hit the proverbial wall Monday when the U.S. Supreme Court refused to hear the company’s appeal of a lower court ruling.
-
First West Coast CME Program on Tick-borne Disease Provides New Data, Insights from Researchers
10/3/2019
Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the U.S., today highlights the first tick-borne disease CME program on the West Coast, Emerging Research, Diagnosis and Treatment of Lyme Disease and Tick-Borne Illness.
-
ViaCyte to Present Preliminary PEC-Direct Clinical Data at Cell & Gene Meeting on the Mesa
10/3/2019
First demonstration of insulin production in patients from a stem cell-derived islet replacement therapy
-
Entos Pharmaceuticals Announces Research, Development and Collaboration Agreement
10/2/2019
Entos Pharmaceuticals Inc. announced it has entered into a research, development and collaboration agreement with a clinical stage biopharmaceutical company focused on the development of novel therapeutic compounds targeting autoimmune and inflammatory diseases.
-
University of California expands U.S. CRISPR-Cas9 patent portfolio with issuance of new patent
10/1/2019
With its 16th U.S. patent, UC now holds largest U.S. CRISPR-Cas9 patent portfolio
-
Vor Biopharma Hires Senior Cell and Gene Therapy Leaders as Chief Technology Officer and Vice President of Research
10/1/2019
Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells for the treatment of cancer, announced senior appointments to its leadership team.
-
Molecular Assemblies Announces $12.2 M Series A Financing to Advance Enzymatic DNA Synthesis for Life Sciences and Data Storage
10/1/2019
Molecular Assemblies, Inc., announced that it has raised a $12.2 million Series A financing led by iSelect Fund and joined by existing investors, Agilent Technologies, Alexandria Venture Investments, and Keshif Ventures.
-
Inscripta Launches the World’s First Benchtop Platform for Digital Genome Engineering
10/1/2019
The Onyx™ platform enables scientists to create libraries of millions of precisely engineered single cells in one experiment through a fully automated workflow